Mercer Global Advisors Inc. ADV Grows Stock Holdings in Integer Holdings Co. (NYSE:ITGR)

Mercer Global Advisors Inc. ADV grew its stake in shares of Integer Holdings Co. (NYSE:ITGR) by 9.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,771 shares of the medical equipment provider’s stock after acquiring an additional 2,546 shares during the period. Mercer Global Advisors Inc. ADV owned 0.09% of Integer worth $3,563,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. GSA Capital Partners LLP purchased a new stake in Integer during the 1st quarter worth about $786,000. Public Employees Retirement Association of Colorado lifted its holdings in shares of Integer by 3,260.1% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 285,439 shares of the medical equipment provider’s stock worth $28,281,000 after buying an additional 276,944 shares in the last quarter. Norges Bank bought a new position in shares of Integer in the fourth quarter valued at approximately $18,697,000. Blue Trust Inc. grew its stake in Integer by 460.4% during the second quarter. Blue Trust Inc. now owns 5,643 shares of the medical equipment provider’s stock valued at $658,000 after acquiring an additional 4,636 shares in the last quarter. Finally, UniSuper Management Pty Ltd bought a new stake in Integer during the 1st quarter worth approximately $976,000. 99.29% of the stock is owned by institutional investors.

Integer Trading Down 1.6 %

Shares of ITGR stock opened at $129.33 on Monday. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.73. The firm has a market cap of $4.33 billion, a P/E ratio of 44.75, a price-to-earnings-growth ratio of 1.81 and a beta of 1.09. The business has a 50-day moving average price of $122.98 and a two-hundred day moving average price of $118.66. Integer Holdings Co. has a 12-month low of $69.40 and a 12-month high of $131.87.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.06. The business had revenue of $436.20 million during the quarter, compared to analyst estimates of $437.00 million. Integer had a return on equity of 11.48% and a net margin of 6.31%. Integer’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.14 earnings per share. Equities analysts anticipate that Integer Holdings Co. will post 5.31 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jean M. Hobby sold 11,960 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the transaction, the director now directly owns 2,280 shares of the company’s stock, valued at $272,824.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Oppenheimer initiated coverage on shares of Integer in a report on Tuesday, July 16th. They issued an “outperform” rating and a $135.00 price target for the company. Benchmark restated a “buy” rating and set a $130.00 target price on shares of Integer in a research report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $133.86.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.